External Validation of Surrogate Indices of Fatty Liver in the General Population: the Bagnacavallo Study.
cross-sectional study
diagnostic techniques and procedures
fatty liver
non-alcoholic fatty liver disease
validation study
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
01 Feb 2021
01 Feb 2021
Historique:
received:
28
12
2020
revised:
17
01
2021
accepted:
24
01
2021
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
5
2
2021
Statut:
epublish
Résumé
We externally validated the fatty liver index (FLI), the lipid accumulation product (LAP), the hepatic steatosis index (HSI), and the Zhejiang University index (ZJU) for the diagnosis of fatty liver (FL) and non-alcoholic fatty liver disease (NAFLD) in the general population. The validation was performed on 2159 citizens of the town of Bagnacavallo (Ravenna, Italy). Calibration was evaluated by calculating the calibration slope and intercept and by inspecting calibration plots; discrimination was evaluated using the c-statistic. The average calibration slope was 1 and the average intercept was 0 for all combinations of outcomes and indices. For the diagnosis of FL, the c-statistic was 0.85 for FLI, 0.83 for ZJU, 0.82 for HSI, and 0.80 for LAP; for the diagnosis of NAFLD, the c-statistic was 0.77 for FLI, 0.76 for ZJU, 0.75 for HSI, and 0.74 for LAP. All indices were strongly correlated with each other. In conclusion, FLI, LAP, HSI, and ZJU perform similarly well to diagnose FL and NAFLD in the Bagnacavallo population, even if FLI has a small advantage as discrimination is concerned.
Identifiants
pubmed: 33535679
pii: jcm10030520
doi: 10.3390/jcm10030520
pmc: PMC7867182
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Gilead Sciences
ID : Fondazione Italiana Fegato
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
BMC Gastroenterol. 2018 Nov 28;18(1):177
pubmed: 30486798
J Clin Epidemiol. 2016 Jun;74:167-76
pubmed: 26772608
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
J Clin Med. 2020 Apr 20;9(4):
pubmed: 32325965
Dig Liver Dis. 2010 Jul;42(7):503-8
pubmed: 19766548
J Clin Epidemiol. 2020 Feb;118:93-99
pubmed: 31605731
Hepatology. 2011 Sep 2;54(3):1082-1090
pubmed: 21618575
Comp Hepatol. 2005 Dec 23;4:10
pubmed: 16375767
Liver Int. 2020 Jun;40(6):1254-1261
pubmed: 32301554
Gastroenterology. 2009 Sep;137(3):865-72
pubmed: 19524579
Gastroenterology. 2020 May;158(7):1999-2014.e1
pubmed: 32044314
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
J Hepatol. 2020 Nov;73(5):1264-1265
pubmed: 32839034
J Hepatol. 2020 Dec;73(6):1307-1309
pubmed: 32890593
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
BMC Gastroenterol. 2010 Aug 25;10:98
pubmed: 20738844
Ann Hepatol. 2020 Jul - Aug;19(4):380-387
pubmed: 32451205
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
J Gastroenterol Hepatol. 2014 Dec;29(12):2006-13
pubmed: 25039333
Dig Liver Dis. 2020 Dec 14;:
pubmed: 33334704
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Obes Res. 1998 Sep;6 Suppl 2:51S-209S
pubmed: 9813653
Sci Rep. 2015 Nov 16;5:16494
pubmed: 26568423
Medicine (Baltimore). 2017 Jul;96(30):e7610
pubmed: 28746214
Hepatology. 2005 Jul;42(1):44-52
pubmed: 15895401
Am J Gastroenterol. 2014 Sep;109(9):1404-14
pubmed: 24957156